Video

Dr. Shah on the Utility of MRD in Frontline Multiple Myeloma

Author(s):

Nina Shah, MD, discusses the utility of minimal residual disease in frontline multiple myeloma.

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the utility of minimal residual disease (MRD) in frontline multiple myeloma.

Although the role of MRD has been explored in clinical trials such as the phase II GRIFFIN study and the phase II MASTER study, its utility remains investigational, explains Shah. Determining a patient's MRD status can provide insight into their prognosis, but it should not impact clinical decisions, says Shah.

Historically, FDA approvals in multiple myeloma have not been based on MRD. As such, basing a patient's treatment on MRD may not be an optimal approach, explains Shah.

However, Shah is hopeful that clinical trials will help the field come to a more definitive conclusion as to its application in the future.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity